FrancophonIA/ELRC3.0 huggingface dataset:
English: Kineret treatment should not be initiated in patients with neutropenia (ANC < 1.5 x 109/l).
Estonian: Patsientidel, kellel tekib neutropeenia (ANC < 1,5 x 109/l)
English: Allergic reactions including anaphylactic reactions, angioedema, urticaria, rash, and pruritus have been reported uncommonly with Kineret.
Estonian: Allergilised reaktsioonid, kaasa arvatud anafülaktilised reaktsioonid, angioödeem, urtikaaria ja kihelus
English: Hyperlink reference not valid.http://www.ema.europa.eu.
Estonian: Täpne teave selle ravimi kohta on Euroopa Ravimiameti kodulehel: http://www.ema.europa.eu.
English: An adverse event profile similar to that seen in adult RA patients was observed in these studies.
Estonian: Neis uuringutes täheldati, et kõrvaltoimete profiil oli sarnane RA-ga patsientide puhul täheldatuga.
English: Injection site reaction Uncommon (≥ 1/1,000 to < 1/100) Rash
Estonian: Infektsioonid ja infestatsioonid Sage (≥ 1/100 kuni < 1/10)
English: INSTRUCTIONS FOR PREPARING AND GIVING AN INJECTION OF KINERET
Estonian: KINERETI SÜSTE ETTEVALMISTAMISE JA SÜSTIMISE JUHISED
English: Kineret treatment should be discontinued in RA patients if a serious infection develops.
Estonian: RA-ga patsientidel tuleb raske infektsiooni tekkimisel Kineret-ravi katkestada.
English: Pharmacokinetic data are lacking in older CAPS patients.
Estonian: Vanemaealiste CAPS-iga patsientide kohta ei ole farmakokineetilisi andmeid.
English: Physicians should exercise caution when administering Kineret to patients with a history of recurring infections or with underlying conditions which may predispose them to infections.
Estonian: Korduvate infektsioonidega või infektsiooni soodustavate seisunditega patsientidele Kinereti manustamisel peab arst olema ettevaatlik.
English: Kineret was studied in a single randomized, blinded multi-center trial in 86 patients with polyarticular course JIA (ages 2-17 years) receiving a dose of 1 mg/kg subcutaneously daily, up to a maximum dose of 100 mg.
Estonian: Kinereti uuriti ühes randomiseeritud pimedas mitmekeskuselises uuringus 86-l patsiendil (vanuses 2...17 eluaastat), kes põdesid polüartikulaarset JIA-d. Neile manustati üks kord ööpäevas subkutaanselt 1 mg/kg, maksimaalne annus oli 100 mg. 50 patsienti, kellel tekkis pärast 12-nädalast avatud uuringueelset perioodi ravimile kliiniline vastus, randomiseeriti Kinereti saavasse rühma (25 patsienti) või platseebot saavasse rühma (25 patsienti), kus neile manustati täiendava 16 nädala jooksul kord ööpäevas ravimit või platseebot.
English: Kineret contains sodium
Estonian: Süstla silinder
English: Kineret is a clear, colourless-to-white solution for injection and is supplied ready for use in a pre-filled syringe.
Estonian: Kineret on selge, värvitu kuni valge süstelahus kasutusvalmis süstlis.
English: Clinical efficacy and safety in Still's disease
Estonian: Kliiniline efektiivsus ja ohutus Stilli tõve korral
English: How do you give your injection?
Estonian: Kuidas ennast süstida?
English: In RA patients the most common and consistently reported treatment-related adverse reactions associated with Kineret were ISRs.
Estonian: Kõige sagedasem ja pidevalt täheldatud Kinereti kõrvaltoime RA-ga patsientidel oli süstekoha reaktsioon.
English: Malignancies
Estonian: SÜSTLID
English: Common (≥ 1/100 to < 1/10)
Estonian: Aeg-ajalt (≥ 1/1000 kuni
English: - The other ingredients are anhydrous citric acid, sodium chloride, disodium edetate dihydrate, polysorbate 80 and sodium hydroxide and water for injections.
Estonian: - Teised koostisosad on veevaba sidrunhape, naatriumkloriid, dinaatriumedetaatdihüdraat,
English: These symptoms are generally mild to moderate and are more common at the start of your treatment.
Estonian: See on üldjuhul kerge kuni mõõdukas ja tekib tavaliselt ravi algul; - peavalud; - vere üldkolesterooli sisalduse suurenemine.
English: Kineret should be used with caution in patients with severe hepatic impairment.
Estonian: Kinereti kasutamisel raske maksakahjustusega patsientidel tuleb olla ettevaatlik.
English: Also persistent low-grade fever, weight loss, and persistent cough can be signs of an infection.
Estonian: Nakkuse nähtudeks võivad olla ka püsivalt väike palavik, kehakaalu langus ja püsiv köha.
English: Method of administration Kineret is administered by subcutaneous injection.
Estonian: Manustamisviis Kinereti manustatakse nahaaluse süstena.
English: No dose adjustment is needed for patients with mild renal impairment (CLcr 60 to 89 ml/min).
Estonian: Kerge neerukahjustusega patsientidel (kreatiniinikliirens 60...89 ml/min) ei ole vaja annust kohandada.
English: No effects on embryo-foetal development in the rabbit were observed at doses 100 times the human dose.
Estonian: 100-kordse inimese annuse (2 mg/kg ööpäevas) manustamisel ei täheldatud mõju küüliku loote arengule.
English: In patients who become neutropenic (ANC < 1.5 x 109/l) the ANC should be monitored closely and Kineret treatment should be discontinued.
Estonian: Neutropeeniaga (ANC < 1,5 x 109/l) patsientidel ei tohi alustada ravi Kineretiga.
English: • the top of the thighs
Estonian: • reite ülaosa,
English: Kineret should be used with caution in patients with moderate renal impairment (CLcr 30 to 59 ml/min).
Estonian: Mõõduka neerukahjustusega patsientidel (kreatiniinikliirens 30...59 ml/min) tuleb Kinareti kasutamisel olla ettevaatlik.
English: X-ray examinations have been undertaken in one clinical study with anakinra.
Estonian: Ühes kliinilises uuringus anakinraga läbiviidud röntgeniuuringud ei näidanud ravimi kahjulikku mõju liigeskõhredele.
English: Patients are usually well-controlled by maintaining the recommended starting dose (1-2 mg/kg/day).
Estonian: Säilitusannus kergekujulise CAPS-i (FCAS-i, kergekujulise MWS-i) korral Patsientide haigusnähte saab tavaliselt soovitatava algannusega (1…2 mg/kg ööpäevas) edukalt kontrolli all hoida.
English: • Patient and caregiver information pack
Estonian: • infopakett patsientidele ja hooldajatele.
English: Uncommon (≥ 1/1,000 to < 1/100) Hepatic enzyme increased Not known (cannot be estimated from the available data)
Estonian: Teadmata (ei saa hinnata olemasolevate andmete alusel)
English: • a pre-filled syringe of Kineret
Estonian: • süstlit Kineretiga;
English: In studies of sepsis, 1,015 patients received Kineret at doses up to 2 mg/kg/hour i.v.
Estonian: Sepsise uuringutes said 1015 patsienti intravenoosselt Kinereti annuses kuni 2 mg/kg tunnis (ligikaudu 35 korda rohkem RA-ga patsientide jaoks soovitatavast annusest) 72-tunnise ravi jooksul.
English: You must not be given live vaccines while being treated with
Estonian: Ravi ajal Kineretiga ei tohi teile elusvaktsiine manustada.
English: Do not shake the pre-filled syringe.
Estonian: Ärge raputage süstlit.
English: - Serious infections such as pneumonia (a chest infection) or infections of the skin can occur during Kineret treatment.
Estonian: Infektsiooni sümptomiteks võivad olla palavik või valus kurk; - rasked infektsioonid, näiteks kopsupõletik või nahainfektsioonid; - trombotsütopeenia (väike trombotsüütide arv).
English: Available data is limited regarding whether Kineret can be continued during serious infections in patients with Still's disease.
Estonian: Kineretiga ravi jätkamise kohta rasket infektsiooni põdevate Stilli tõvega patsientidel on saadaolevad andmed piiratud.
English: • The prescribed dose of Kineret
Estonian: • Kinereti määratud annus;
English: Anakinra had no observed effect on the fertility, early development, embryo-foetal development, or peri- and postnatal development in the rat at doses up to 100 times the human dose (2 mg/kg/day).
Estonian: Kuni 100-kordselt inimestele manustatava annuse ületamisel ei täheldatud rottidel anakinra mõju viljakusele, varasele ja hilisele loote arengule ega sünnieelsele ja sünnijärgsele arengule.
English: Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.
Estonian: Kineret 100 mg/0,67 ml süstelahus süstlis
English: What should you do before you give yourself or your child a subcutaneous injection of Kineret?
Estonian: Mida teha enne Kinereti nahaalust süstimist?
English: The most common reason for withdrawal from study in Kineret-treated RA patients was injection site reaction.
Estonian: Süstekoha reaktsioon oli kõige levinum Kineretiga ravitud RA-ga haigete uuringust lahkumise põhjus.
English: B.
Estonian: Joonis B
English: You can now use the pre-filled syringe as described in the
Estonian: Nüüd võite süstlit kasutada, nagu on kirjeldatud lõigus „Kuhu tuleks ennast süstida?” ja lõigus
English: SC
Estonian: Joonis C
English: Kineret.
Estonian: KÕLBLIKKUSAEG
English: The recommended dose of Kineret is 100 mg administered once a day by subcutaneous injection.
Estonian: Kinereti manustatakse üks kord ööpäevas nahaaluse süstena soovitatava annusena 100 mg. Annus tuleb manustada iga päev ligikaudu samal ajal.
English: EU/1/06/339/003 Preotact
Estonian: EU/1/06/339/003
English: 1.61 mg (1.4 mg/ml)
Estonian: 1,61 mg (1,4 mg/ml) 2 pensüstlit
English: Subcutaneous powder: dual-chamber cartridge (glass) in pre-filled pen; solvent: dual-chamber cartridge (glass) in pre-filled pen
Estonian: Subkutaanne Pulber: kahekambriline kolbampull (klaas) pensüstlis; lahusti: kahekambriline kolbampull (klaas) pensüstlis
English: 2 pre-filled pens
Estonian: 100 µg Süstelahuse pulber ja lahusti
English: Pack size
Estonian: Tugevu s
English: Ref.: EMEA/264573/2009 EMEA/H/C/1019
Estonian: Viide: EMEA/264573/2009 EMEA/H/C/1019
English: The name of the medicine was changed to Alisade on 25 March 2009.
Estonian: Ravimi nimetus muudeti Alisadeks 25. märtsil
English: This authorisation was based on the authorisation granted to Avamys in January 2008 (‘informed consent').
Estonian: Müügiluba põhines jaanuaris 2008 antud Avamysi müügiloal (teabel põhineva nõusoleku alusel).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Fluticasone Furoate GSK to Glaxo Group Ltd on 6 October 2008.
Estonian: Euroopa Komisjon andis Fluticasone Furoate GSK müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Glaxo Group Ltd 6. oktoobril 2008.
English: However, it was not possible to determine if Alisade worked in children below the age of six years, because there were too few children below this age included the studies.
Estonian: Uuringutes ei olnud siiski võimalik määrata, kas Alisade toimib ka alla kuueaastastel lastel, sest selles vanuses lapsi osales uuringutes liiga vähe.
English: This is generally mild or moderate and tends to affect adults who have used Alisade for more than six weeks.
Estonian: See on üldiselt kerge kuni mõõdukas ja näib peamiselt esinevat täiskasvanutel, kes on kasutanud Alisadet üle kuue nädala.
English: Previously known as Fluticasone Furoate GSK.
Estonian: Varasem nimetus Fluticasone Furoate GSK.
English: The Committee recommended that Alisade be given marketing authorisation.
Estonian: Komitee soovitas anda Alisadele müügiloa.
English: fluticasone furoate EPAR summary for the public
Estonian: flutikasoonfuroaat Kokkuvõte üldsusele
English: Other information about Alisade:
Estonian: Muu teave Alisade kohta
English: Alisade should only be used for as long as the patient is exposed to the allergen, such as pollen, house dust mites or other animals.
Estonian: Alisadet tuleb kasutada ainult seni, kuni patsient puutub kokku allergeeniga, nt õietolmu, tolmulestade või muude loomadega.
English: The first four studies looked at Alisade used in patients aged 12 years or over: three were short-term studies lasting two weeks and involved a total of 886 patients with seasonal allergic rhinitis (hay fever), while the fourth lasted four weeks and involved 302 patients with perennial (nonseasonal) allergies, such as allergies to animals.
Estonian: Neist esimeses neljas uuringus vaadeldi Alisade kasutamist vähemalt 12-aastastel patsientidel: kolm olid lühiajalised kahenädalased uuringud, milles osales kokku 886 hooajalise allergilise riniidiga (heinanohuga) patsienti; neljas uuring kestis neli nädalat ja selles osales 302 patsienti, kellel oli aastaringne allergia, näiteks loomade vastu.
English: Alisade was compared with placebo (a dummy treatment) in six main studies involving almost 2,500 patients.
Estonian: Alisadet võrreldi platseeboga (näiva ravimiga) kuues põhiuuringus, milles osales ligikaudu 2500 patsienti.
English: Alisade is a nasal spray that contains the active substance fluticasone furoate.
Estonian: Alisade on ninapihus, mis sisaldab toimeainena flutikasoonfuroaati.
English: Alisade is used to treat the symptoms of allergic rhinitis.
Estonian: Alisadet kasutatakse allergilise riniidi sümptomite raviks.
English: The most common side effect with Alisade (seen in more than 1 patient in 10) is epistaxis (nosebleeds).
Estonian: Alisade kõige sagedam kõrvalnäht (esinenud enam kui ühel patsiendil kümnest) on ninaverejooks.
English: Why has Alisade been approved?
Estonian: Miks Alisade heaks kiideti?
English: The full EPAR for Alisade can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Alisade kohta leiate siit.
English: What is the risk associated with Alisade?
Estonian: Mis riskid kaasnevad Alisadega?
English: The recommended dose of Alisade for patients aged 12 years and over is two sprays in each nostril once a day.
Estonian: Alisade soovitatav annus vähemalt 12-aastastele patsientidele on kaks pihustuskorda kummassegi sõõrmesse üks kord ööpäevas.
English: What is Alisade?
Estonian: Mis on Alisade?
English: In the studies of seasonal allergic rhinitis in patients aged 12 years or over, Alisade reduced symptom scores from around 9 points at the start of the study by between 3.6 and 5.4 points over two weeks, compared with a reduction of 2.3 to 3.7 points with placebo.
Estonian: Hooajalise allergilise riniidiga vähemalt 12-aastaste patsientide uuringutes vähendas Alisade sümptomite punktisummat ravialgselt 9 punktilt kahe ravinädala järel 3,6-5,4 punkti võrra, samas kui platseebo vähendas punktisummat 2,3-3,7 punkti võrra.
English: Alisade is for use in patients aged six years and over.
Estonian: Alisadet kasutatakse vähemalt 6-aastastel patsientidel.
English: Alisade should not be used in people who are allergic to fluticasone furoate or any of the other ingredients.
Estonian: Alisadet ei tohi kasutada patsiendid, kes võivad olla flutikasoonfuroaadi või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The effects of Alisade were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Alisade toimet muude katsetega.
English: For the full list of all side effects reported with Alisade, see the Package Leaflet.
Estonian: Alisade kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: In the study of perennial allergic rhinitis, Alisade had reduced scores by 3.6 points after four weeks, compared with a reduction of 2.8 points with placebo.
Estonian: Aastaringse allergilise riniidi korral vähendas Alisade sümptomite punktisummat nelja ravinädala järel 3,6 punkti võrra, samas kui platseebo vähendas punktisummat 2,8 punkti võrra.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Alisade's benefits are greater than its risks for the treatment of the symptoms of allergic rhinitis in patients aged six years or over.
Estonian: Inimravimite komitee jõudis otsusele, et Alisade kasulikkus allergilise riniidi sümptomaatilises ravis vähemalt kuueaastastel patsientidel on suurem kui sellega kaasnevad riskid.
English: The active substance in Alisade, fluticasone furoate, is a corticosteroid.
Estonian: Alisade toimeaine flutikasoonfuroaat on kortikosteroid.
English: How is Alisade used?
Estonian: Kuidas Alisadet kasutatakse?
English: How has Alisade been studied?
Estonian: Kuidas Alisadet uuriti?
English: Alisade was more effective than placebo at reducing symptoms of allergic rhinitis in patients aged six years and over.
Estonian: Alisade vähendas allergilise riniidi sümptomeid vähemalt 6-aastastel patsientidel efektiivsemalt kui platseebo.
English: What is Alisade used for?
Estonian: Milleks Alisadet kasutatakse?
English: What benefit has Alisade shown during the studies?
Estonian: Milles seisneb uuringute põhjal Alisade kasulikkus?
English: How does Alisade work?
Estonian: Kuidas Alisade toimib?
English: EMA/354096/2016 EMEA/H/C/004172
Estonian: EMA/354096/2016 EMA/H/C/004172
English: Two medicines are bioequivalent when they produce the same levels of the active substances in the body.
Estonian: Kaks ravimit on bioekvivalentsed, kui mõlemad ravimid tekitavad organismis sama toimeainesisalduse.
English: In its letter notifying the Agency of the withdrawal of application, the company stated that the time required to generate the supporting data makes this product unviable.
Estonian: Ettevõtte kirjas, milles ta teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, märgib ettevõte, et toetavate andmete hankimiseks kuluv aeg muudab selle ravimi ebaotstarbekaks.
English: The CHMP was concerned that there was uncertainty about how the bioequivalence study was conducted.
Estonian: Inimravimite komiteel oli kahtlusi seoses bioekvivalentsuse uuringu läbiviimise metoodikaga.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the medicine could not have been approved based on the data presented by the company.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et ettevõtte esitatud andmete alusel ei saa ravimit heaks kiita.
English: The CHMP also considered that data from the study do not convincingly establish that Alendronic Acid/Colecalciferol Mylan is sufficiently similar to the reference medicine, Fosavance.
Estonian: Inimravimite komitee leidis ka, et uuringuandmed ei näita veenvalt, et Alendronic Acid/Colecalciferol Mylan on piisavalt sarnane võrdlusraviga Fosavance.
English: Alendronic acid reduces the loss of bone tissue and colecalciferol, also known as vitamin D3, increases the absorption of calcium and formation of bone.
Estonian: Alendroonhape vähendab luukoe kadu ning kolekaltsiferool (teise nimetusega vitamiin D3) suurendab kaltsiumi imendumist ja luukoe moodustumist.
English: Because Alendronic Acid/Colecalciferol Mylan is a generic medicine, the company had presented results of a study to determine that Alendronic Acid/Colecalciferol Mylan is bioequivalent to the reference medicine, Fosavance.
Estonian: Et Alendronic Acid / Colecaltciferol Mylan on geneeriline ravim, esitas ettevõte uuringu tulemused, milles näidati Alendronic Acid / Colecalciferol Mylani bioekvivalentsust võrdlusravimiga Fosavance.
English: Based on the review of the data, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Alendronic Acid/Colecalciferol Mylan could not have been approved for the treatment of postmenopausal osteoporosis in women at risk of vitamin D insufficiency.
Estonian: Tuginedes esitatud andmete analüüsile, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et ravimi Alendronic Acid/Colecalciferol Mylan kasutamist D-vitamiini vaeguse riskiga menopausijärgses eas naistel osteoporoosi raviks ei ole võimalik heaks kiita.
English: This means that Alendronic Acid/Colecalciferol Mylan was intended to be similar to a ‘reference medicine' already authorised in the European Union called Fosavance.
Estonian: See tähendab, et Alendronic Acid / Colecalciferol Mylan pidi olema sarnane võrdlusravimiga Fosavance, millel juba on Euroopa Liidus müügiluba.
English: It was expected to reduce the risk of fractures (broken bones) in the spine and the hip.
Estonian: Eeldati, et ravim vähendab lülisamba ja puusamurdude riski.
English: On 27 May 2016, Mylan SAS officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Alendronic Acid/Colecalciferol Mylan, for the treatment of postmenopausal osteoporosis in women at risk of vitamin D deficiency.
Estonian: Mylan SAS teatas 27. mail 2016 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Alendronic Acid / Colecalciferol Mylan müügiloa taotlus.
English: What is Alendronic Acid/Colecalciferol Mylan?
Estonian: Mis on Alendronic Acid / Colecalciferol Mylan?
English: Alendronic Acid/Colecalciferol Mylan was to be used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of insufficient vitamin-D levels.
Estonian: Alendronic Acidi / Colecalciferol Mylani kavatseti kasutada osteoporoosi (haigus, mis muudab luud hapraks) raviks menopausijärgses eas naistel, kellel on D-vitamiini vaeguse risk.
English: The company informed the CHMP that this withdrawal has no consequences for patients.
Estonian: Ettevõte teatas inimravimite komiteele, et taotluse tagasivõtmine ei mõjuta patsiente, sest puuduvad käimasolevad kliinilised uuringud või eriloaga kasutamise programmid.
English: Alendronic Acid/Colecalciferol Mylan was developed as a ‘generic medicine'.
Estonian: Alendronic Acid / Colecalciferol Mylan töötati välja geneerilise ravimina.
English: Alendronic Acid/Colecalciferol Mylan is a medicine that contains two active substances: alendronic acid and colecalciferol.
Estonian: Alendronic Acid / Colecalciferol Mylan on ravim, mis sisaldab toimainetena alendroonhapet ja kolekaltsiferooli.
English: Alendronic Acid/Colecalciferol Mylan is expected to work in the same way as the reference medicine, Fosavance.
Estonian: Alendronic Acid / Colecalciferol Mylani eeldatav toime on samalaadne võrdlusravimi Fosavance toimega.
English: How is Alendronic Acid/Colecalciferol Mylan expected to work?
Estonian: Milline on Alendronic Acid / Colecalciferol Mylani eeldatav toime?
English: What is Adlumiz?
Estonian: Mis on Adlumiz?
English: This meant that a thorough evaluation of potential risks with Adlumiz was not possible.
Estonian: See tähendas, et Adlumizi võimalike riskide põhjalik hindamine ei olnud võimalik.
English: It was to be available as 100 mg tablets to be taken by mouth.
Estonian: Seda kavatseti turustada 100 mg suukaudsete tablettidena.
English: The company presented results of two main studies involving a total of around 1,000 non-small cell lung cancer patients with cachexia.
Estonian: Ettevõte esitas kahe põhiuuringu tulemused, milles osales kokku ligikaudu 1000 kahheksiaga mitteväikerakulise kopsuvähiga patsienti.
English: How does Adlumiz work?
Estonian: Kuidas Adlumiz toimib?
English: In addition, following an inspection at clinical study sites, CHMP considered that the safety data on the medicine had not been recorded adequately.
Estonian: Lisaks, pärast kliinilise uuringu keskuste kontrolli oli inimravimite komitee arvamusel, et ravimi ohutusandmed ei ole piisavalt hästi registreeritud.
English: The company that applied for authorisation is Helsinn Birex Pharmaceuticals Ltd.
Estonian: Müügiluba taotles Helsinn Birex Pharmaceuticals Ltd.
English: Therefore the CHMP was of the opinion that the benefits of Adlumiz did not outweigh its risks and recommended that it be refused marketing authorisation.
Estonian: Inimravimite komitee oli seepärast arvamusel, et Adlumizi kasulikkus ei ületa sellega seotud riske, ja soovitas müügiloa andmisest keelduda.
English: Activation of the receptor causes release of substances in the body which are expected to act in the brain to increase appetite and prevent weight loss.
Estonian: Retseptori aktivatsioon põhjustab organismis selliste ainete vabanemise, mis eeldatavalt toimivad ajus isu suurendavana ja kaalulangust ennetavana.
English: On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Adlumiz, intended for the treatment of anorexia, cachexia or unintended weight loss in patients with non-small cell lung cancer.
Estonian: 18. mail 2017 võttis inimravimite komitee vastu negatiivse arvamuse, soovitades keelduda müügiloa andmisest ravimile Adlumiz, mida kavatseti kasutada mitteväikerakulise kopsuvähiga patsientidel anoreksia, kahheksia või soovimatu kaalulanguse raviks.